Three People, One Injection, and a Safety Board That Said Continue
Life Biosciences reported the first human data for ER-100, a partial reprogramming injection, in three people with glaucoma. No serious adverse events at day 56. Two showed visual-field gains. It is not a cure.
The first human test of partial epigenetic reprogramming is a glaucoma trial, not a fountain
At Eyecelerator, alongside the American Academy of Ophthalmology meeting in New Orleans, Sharon Rosenzweig-Lipson stood up as chief scientific officer of Life Biosciences and described three people. Each had open-angle glaucoma. Each received one injection into the eye of a virus carrying three genes: OCT4, SOX2 and KLF4. The genes stay quiet unless the person takes doxycycline. They took it for 56 days. A steroid taper ran alongside, because the immune system does not ignore a viral vector.
Through day 56, at a dose of 2 times 10 to the 11 vector genomes, the company reported no serious adverse events, no dose-limiting toxicities, and no adverse events of special interest. Events that did occur were put down to the injection, the steroid, or illnesses the patients already had. An independent safety board told the company it could triple the dose.
Two of the three also did better on a Humphrey visual field test, the exam that asks whether you can see a light at points across your vision. In both, at least 28 percent of tested points improved by more than 4 decibels at day 56. Rosenzweig-Lipson said existing drugs mostly lower eye pressure, and that pressure control does not always stop the loss. Retinal ganglion cells do not grow back. Lost field is usually gone.
The trial is registered as NCT07290244. It is open-label. It was built to ask whether the injection could be tolerated. Longevity.Technology, writing up the presentation, said three patients and 56 days would be an athletic leap to a claim that cellular rejuvenation works in humans. David Sinclair, whose lab built much of the mouse work, told Lifespan magazine the result was an encouraging first step. He is not the trial's treating physician.
The fourth Yamanaka factor, c-MYC, was left out because it is the one most tied to cancer risk. The doxycycline switch is the other brake. The eye was chosen because delivery is local and because mouse work had already restored vision there. A systemic age-reversal claim is not what was injected.
Key Facts
- Presentation: Eyecelerator at AAO 2026, New Orleans, data reported 8–12 October
- Three participants, open-angle glaucoma, dose level 1, day 56
- No serious adverse events or dose-limiting toxicities reported
- Safety board cleared escalation from 2 times 10 to the 11 to 6 times 10 to the 11 vector genomes
- Two of three: at least 28 percent of visual-field points improved by more than 4 decibels
- Genes: OCT4, SOX2, KLF4. No c-MYC. Expression requires oral doxycycline
- Sources: Longevity.Technology, Glaucoma Physician, Life Biosciences
Why This Matters
The field has had persuasive mouse graphs for years. A human who can detect a light at a point they missed is a different kind of evidence, and a much smaller one. The safety board's yes is the result this trial was designed to produce. The visual field is a hint riding on top of it.
What We Don't Know Yet
Three people, no placebo, 56 days, company-presented data. We do not have a peer-reviewed paper, a longer follow-up, or a count of how many points worsened. Improvement on a field test can move around from visit to visit. A dose increase is not a proof of reversal. Glaucoma is not aging in general, and this injection is not a pill for the rest of the body.